Loading...

NV N

NV

NOVO NORDISK A S

(NVO)

2026 6-K

Share Repurchase Program

8 Jun '26

Share Repurchase Program

1 Jun '26

Share Repurchase Program

27 May '26

EU Approval Update

22 May '26

6-K Filing

22 May '26

Share Repurchase Plan

18 May '26

Executive Transactions

13 May '26

Q1 2026 Financial Update

6 May '26

Share Buyback Update

5 May '26

Share Repurchase Update

27 Apr '26

Share Buyback Plan

20 Apr '26

Etavopivat Trial Success

20 Apr '26

Share Repurchase Update

13 Apr '26

Share Repurchase Update

7 Apr '26

Share Repurchase Plan

30 Mar '26

Company Structure Update

27 Mar '26

FDA Approval

27 Mar '26

Annual Meeting Results

26 Mar '26

Share Buyback Program

23 Mar '26

Wegovy® HD Approved

20 Mar '26

Share Repurchase Program

17 Mar '26

Share Repurchase Announcement

9 Mar '26

Board Elections Completed

2 Mar '26

Share Buyback Program

2 Mar '26

Share Repurchase Program

23 Feb '26

Trial Results Report

23 Feb '26

Annual Meeting Notice

20 Feb '26

Share Repurchase Program

17 Feb '26

Board Transactions

11 Feb '26

Executive Share Transaction

10 Feb '26

Share Buyback Program

9 Feb '26

Share Transactions Report

5 Feb '26

Share Buyback Initiated

5 Feb '26

Annual Report Released

5 Feb '26

CEO Remuneration Report

4 Feb '26

2025 Financial Performance

3 Feb '26

2026 Sales Outlook

3 Feb '26

CagriSema Results

2 Feb '26

Board Change

2 Feb '26

Wegovy® Pill Approved

23 Dec '25

Positive Trial Results

25 Nov '25

Evoke Trials Results

24 Nov '25

Share Transaction Update

17 Nov '25

Board Changes

14 Nov '25

Board Candidate Update

14 Nov '25

Board Transactions

12 Nov '25

Drug Price Agreement

7 Nov '25

Financial Update

5 Nov '25

Acquisition Proposal

30 Oct '25

Extraordinary Meeting Notice

21 Oct '25

Board Meeting Announcement

21 Oct '25

Acquisition Announcement

9 Oct '25

Streamlining Operations

10 Sep '25

Share Transactions Report

19 Aug '25

FDA Approval for Wegovy

15 Aug '25

Executive Share Sale

14 Aug '25

Share Transactions Report

8 Aug '25

Share Transactions

8 Aug '25

Financial Update

6 Aug '25

Mini-Tender Offer

4 Aug '25

Leadership Change

29 Jul '25

Sales Outlook Update

29 Jul '25

Clinical Development Update

13 Jun '25

CEO Transition

16 May '25

Share Transactions

9 May '25

Financial Growth Report

7 May '25

Management Changes

3 Apr '25

Annual Meeting Highlights

31 Mar '25

CagriSema Trial Results

10 Mar '25

Annual General Meeting

27 Feb '25

Board Transactions

7 Feb '25

Share Transactions Report

6 Feb '25

Strong Financial Growth

5 Feb '25

Disclosure Notice

5 Feb '25

Remuneration Report 2024

5 Feb '25

Share Repurchase Update

4 Feb '25

Share Buyback Update

27 Jan '25

Amycretin Trial Results

24 Jan '25

Share Buyback Program

21 Jan '25

Semaglutide Trial Results

17 Jan '25

Share Buyback Program

15 Jan '25

Share Buyback Program

20 Dec '24

CagriSema Trial Results

20 Dec '24

Acquisition Completed

18 Dec '24

Share Repurchase Plan

16 Dec '24

Acquisition Update

16 Dec '24

Positive Ozempic Update

13 Dec '24

Share Buyback Program

9 Dec '24

Acquisition Approved

6 Dec '24

Share Buyback Program

2 Dec '24

Share Repurchase Plan

25 Nov '24

Share Transaction Notification

19 Nov '24

Share Repurchase Program

18 Nov '24

Share Purchase Report

14 Nov '24

Share Transactions Report

13 Nov '24

Share Trading Report

8 Nov '24

Share Buyback Program

8 Nov '24

Share Repurchase Announcement

8 Nov '24

Insider Trading Report

8 Nov '24

Board Transactions

7 Nov '24

Strong Sales Growth

6 Nov '24

Share Repurchase Update

5 Nov '24

Trial Results Announced

1 Nov '24

Share Buyback Update

28 Oct '24

Share Buyback Program

21 Oct '24

SOUL Trial Results

21 Oct '24

Share Repurchase Update

15 Oct '24

Share Buyback Program

7 Oct '24

Share Repurchase Program

30 Sep '24

Share Buyback Update

24 Sep '24

Clinical Trial Results

20 Sep '24

Share Repurchase Program

16 Sep '24

Share Repurchase Program

9 Sep '24

Share Buyback Program

9 Sep '24

Board Trading Report

30 Aug '24

Share Repurchase Update

26 Aug '24

Share Transactions Report

21 Aug '24

Share Buyback Program

19 Aug '24

Share Trading Disclosure

14 Aug '24

Share Buyback Program

12 Aug '24

Share Transactions

12 Aug '24

Share Transactions Report

9 Aug '24

Insider Share Trading

9 Aug '24

Strong Financial Growth

7 Aug '24

Share Repurchase Update

6 Aug '24

Share Repurchase Plan

29 Jul '24

Wegovy® Label Update

25 Jul '24

Share Repurchase Program

22 Jul '24

Share Repurchase Update

15 Jul '24

FDA Response Letter

11 Jul '24

Share Buyback Update

9 Jul '24

Share Repurchase Program

2 Jul '24

Trial Termination Announced

26 Jun '24

Share Buyback Program

24 Jun '24

Share Repurchase Program

17 Jun '24

Share Repurchase Update

10 Jun '24

Share Repurchase Update

3 Jun '24

Share Buyback Update

28 May '24

Share Repurchase Initiated

17 May '24

Executive Share Sale

15 May '24

Mim8 Trial Results

13 May '24

Share Trading Update

13 May '24

Board Share Sale

6 May '24

Share Repurchase Initiative

6 May '24

Share Repurchase Agreement

6 May '24

Executive Share Sales

6 May '24

Q1 2024 Financials

2 May '24

Share Buyback Update

1 May '24

Voting Rights Update

26 Apr '24

Share Capital Details

25 Apr '24

Share Capital Reduction

25 Apr '24

Share Repurchase Update

22 Apr '24

Share Trading Report

17 Apr '24

Share Buyback Program

17 Apr '24

Share Buyback Update

8 Apr '24

Share Repurchase Program

2 Apr '24

Share Repurchase Program

1 Apr '24

Articles of Association

25 Mar '24

Positive Regulatory Opinion

21 Mar '24

Annual Meeting Summary

21 Mar '24

Share Repurchase Program

18 Mar '24

Share Buyback Update

11 Mar '24

Wegovy Approval Announced

8 Mar '24

Kidney Risk Reduction

5 Mar '24

Share Repurchase Update

4 Mar '24

Share Buyback Program

26 Feb '24

Annual Meeting Notice

22 Feb '24

Share Repurchase Update

22 Feb '24

Share Trading Report

14 Feb '24

Share Repurchase Program

13 Feb '24

Share Sales Report

12 Feb '24

Share Transaction Report

9 Feb '24

Board Transactions

7 Feb '24

Share Repurchase Program

6 Feb '24

Site Acquisition

5 Feb '24

Share Transactions Report

2 Feb '24

Strong Financial Growth

31 Jan '24

Remuneration Report

31 Jan '24

Share Repurchase Program

30 Jan '24

Share Repurchase Plan

22 Jan '24

Share Buyback Update

16 Jan '24

Share Transactions

11 Jan '24

Clinical Trial Results

8 Jan '24

Share Repurchase Update

8 Jan '24

External Links:

SEC

On May 6, 2026, Novo Nordisk announced a share repurchase program of up to DKK 15 billion over 12 months, with DKK 11.2 billion allocated to repurchasing B shares by February 1, 2027, and has already bought back 3,130,000 shares at an average price of DKK 287.85 as of May 29, 2026.

AI Assistant

NOVO NORDISK A S

2026

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.